LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
2 \0 G6 ?- K' A' xTHERAPE UTIC PERSPECTIVES# E$ D) A; k: B9 }
J. Mazieres, S. Peters
$ D2 R' p" `: WIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
* C/ n2 L6 |: `; n! b' Moutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted1 b- M$ S. x0 {. X# m' o
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her24 m. n# [# z' @
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations! k9 S6 V e% |, o1 m9 Q8 }+ I
and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
% H3 D* W3 H0 _: w7 odisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for. b1 \' }6 `/ a0 A0 T
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to$ L, R: } a- {/ u" W6 m
lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and" C6 O6 ^/ y* t1 I2 P" C
22.9 months for respectively early stage and stag e IV patients.
* `9 ~" K0 |+ e' LConclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,8 p8 q( G. l1 u2 L/ P. C) k
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .( z# _7 Z0 n% W. R. \* J
HER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
9 R+ ]7 q6 H- ?/ X) }clinicaltrials.; @5 P0 ^/ L9 S+ \; F/ B
|
显身卡
